Trial Profile
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Endoxifen (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- 17 Sep 2021 Results (n=80) assessing the population pharmacokinetics (PK) of Z-endoxifen in patients with treatment-refractory gynecologic malignancies, desmoid tumors or hormone receptor-positive solid tumors from Mayo Clinic (NCT01327781) and National Cancer Inst (NCI, NCT01273168) trials, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.
- 30 Aug 2017 Results published in the Journal of Clinical Oncology
- 06 Jun 2017 Results assessing tumor and circulating cell free (cf) DNA mutations, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.